Overview: Immunofixation Electrophoresis Urine TestIntroduction: The Immunofixation Electrophoresis Urine Test detects abnormal proteins in urine to diagnose multiple myeloma, causing bone pain or fatigue. Following 2023 NCCN guidelines, it uses immunoassays for high specificity, supporting cancer screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in clinical pathology for patients with suspected multiple myeloma.
Other Names: IFE Urine Assay, Myeloma Protein Test.
FDA Status: Laboratory-developed test (LDT), meeting clinical pathology standards for diagnostic accuracy.
Historical Milestone: Immunofixation electrophoresis began in the 1970s with myeloma research. Urine-based methods improved in the 1990s, enhancing diagnostic precision.
Purpose: Detects abnormal proteins (e.g., Bence Jones proteins) to diagnose multiple myeloma, guides treatment, and evaluates patients with bone pain or fatigue.
Test Parameters: 1. Immunofixation Electrophoresis
Pretest Condition: No fasting required. Collect 24-hour or random urine at any time. Report history of bone pain, fatigue, or renal issues.
Specimen: 50-100 mL 24-hour urine (sterile container) or 5-20 mL random urine (sterile container). Transport in a biohazard bag within 2 hours.
Sample Stability at Room Temperature: 2 hours
Sample Stability at Refrigeration: 24 hours
Sample Stability at Frozen: Not frozen
Medical History: Document bone pain, fatigue, renal issues, or family history of myeloma. Include current medications and recent symptoms.
Consent: Written consent required, detailing the tests purpose, myeloma implications, and potential need for oncology treatment.
Procedural Considerations: Uses immunofixation electrophoresis to detect abnormal proteins. Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for myeloma screening.
Factors Affecting Result Accuracy: Improper sample collection or contamination can affect results. Incomplete 24-hour urine collection may reduce accuracy.
Clinical Significance: Monoclonal proteins (e.g., Bence Jones) confirm multiple myeloma, guiding chemotherapy or transplant. Negative results may require serum testing.
Specialist Consultation: Consult an oncologist or hematologist for result interpretation and treatment planning.
Additional Supporting Tests: Serum protein electrophoresis, free light chain assay, or bone marrow biopsy to confirm multiple myeloma.
Test Limitations: Not specific to myeloma; other conditions may produce monoclonal proteins. Clinical correlation is needed.
References: NCCN Multiple Myeloma Guidelines, 2023; Blood, Kyle RA, 2022.
